Mana.bio has garnered a significant $19.5M in seed funding to propel their biotechnology venture focusing on programmable drug delivery. This Tel Aviv startup has captured the confidence and capital of prominent investors like Andreessen Horowitz Bio + Health and Base4 Capital. In a noteworthy collaboration, the round also saw substantial backing from NFX, LionBird, and Technion Institute of Technology.